Atrial Fibrillation Anticoagulation Pathway

Clinical Disclaimer: These algorithms are clinical decision aids validated for non-valvular atrial fibrillation. OAC initiation must involve shared decision-making, considering patient values, absolute stroke risk, and absolute bleeding risk.

Clinical Application & Nuances

1. Warning: NOACs in Rheumatic Heart Disease

Absolute Contraindication: In India, Rheumatic Heart Disease (RHD) remains highly prevalent, though the incidence is reducing. Patients with AFib and moderate-to-severe mitral stenosis (or mechanical heart valves) have "Valvular AF." NOACs (Apixaban, Rivaroxaban, Dabigatran) are strictly contraindicated in these patients as they fail to prevent valve thrombosis and stroke. You MUST prescribe a Vitamin K Antagonist (Warfarin/Acitrom) with INR monitoring. The VKA / Warfarin Titration pathway sets the target INR and the dose adjustment.

2. Female Sex, and Why the Score Itself Changed in 2024

Female sex is a risk modifier, not an independent risk factor. In the absence of other CHA₂DS₂-VASc factors, a biological female scores a 1, but this does NOT confer significant stroke risk, and OAC is NOT recommended on this basis alone.

Practice advisory, 2024 ESC. The 2024 ESC atrial fibrillation guideline has acted on exactly this point and replaced CHA₂DS₂-VASc with CHA₂DS₂-VA, removing sex from the score entirely. A woman with no other risk factor now scores 0 rather than 1, which is what the clinical evidence supported all along. The 2023 ACC/AHA guideline took a different route: it retained CHA₂DS₂-VASc as one of several validated instruments and recommends anticoagulation on the magnitude of annual risk, roughly 2% or more per year, rather than on any single score.

This engine continues to compute CHA₂DS₂-VASc, which remains the instrument in widest use in Indian practice and the one underlying the CSI consensus. Read the sex point off the score rather than into it: if the only reason a patient reaches 1 is female sex, the 2024 ESC position and this module agree that anticoagulation is not indicated on that basis. Where a patient is being managed to a European protocol, subtract the sex point and use the CHA₂DS₂-VA threshold instead.

3. The R₂CHA₂DS₂-VASc Upgrade

Renal impairment is a potent, independent predictor of stroke in AFib. The R₂CHA₂DS₂-VASc score assigns 2 points for a Creatinine Clearance < 60 mL/min. This improves net reclassification, identifying high-risk patients who might otherwise falsely appear as 'low risk' on the standard scale.

4. The HAS-BLED Fallacy

A high HAS-BLED score (≥ 3) should never be used in isolation to deny a patient OAC if their stroke risk is high. It should be used to flag the need for closer monitoring and to actively correct modifiable bleeding risks (e.g., optimising BP, stopping NSAIDs, reducing alcohol intake).

5. NOACs vs. Warfarin (VKA)

NOACs (Apixaban, Rivaroxaban, Dabigatran): Recommended as first-line therapy over Warfarin in eligible (non-valvular) patients with AFib due to a significantly lower risk of intracranial haemorrhage and no need for routine INR monitoring.
Renal Dosing: All NOACs require dose reduction in severe renal impairment. Dabigatran is heavily renally cleared and should be avoided in severe CKD; Apixaban is the preferred choice in advanced kidney disease.

Abbreviations: ACC/AHA (American College of Cardiology / American Heart Association) · AF (Atrial Fibrillation) · AFib (Atrial Fibrillation) · AST/ALT (Aspartate Aminotransferase / Alanine Aminotransferase) · BP (Blood Pressure) · CHA₂DS₂-VA (CHA₂DS₂-VASc With the Sex Category Point Removed (2024 European Society of Cardiology Version)) · CHA₂DS₂-VASc (Congestive Heart Failure, Hypertension, Age ≥ 75 (2 Points), Diabetes, Stroke (2 Points), Vascular Disease, Age 65-74, Sex Category) · CHF (Congestive Heart Failure) · CKD (Chronic Kidney Disease) · Cr (Creatinine) · CrCl (Creatinine Clearance) · CSI (Cardiological Society of India) · ESC (European Society of Cardiology) · HAS-BLED (Hypertension, Abnormal Renal or Liver Function, Stroke, Bleeding History, Labile INR, Elderly, Drugs or Alcohol) · INR (International Normalised Ratio) · LV (Left Ventricular) · MI (Myocardial Infarction) · NOAC (Non-Vitamin K Oral Anticoagulant) · NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) · OAC (Oral Anticoagulant) · PAD (Peripheral Arterial Disease) · R₂CHA₂DS₂-VASc (CHA₂DS₂-VASc With Renal Impairment Added (2 Points for Creatinine Clearance < 60 mL/min)) · RHD (Rheumatic Heart Disease) · TIA (Transient Ischaemic Attack) · TTR (Time in Therapeutic Range) · VKA (Vitamin K Antagonist)

Atrial Fibrillation Anticoagulation Pathway

1. Core Patient Profile

2. Stroke Risk Factors (CHA₂DS₂-VASc)

3. Bleeding Specific Factors (HAS-BLED)